Immunological and haematological investigations on patients with adverse reactions during treatment with RMP plus INH once-weekly.
D000917:Antibody Formation; D001666:Binding Sites, Antibody; D001772:Blood Cell Count; D002986:Clinical Trials as Topic; D004912:Erythrocytes / Q000276:immunology; D005260:Female; D006801:Humans; D007490:Iproniazid / Q000008:administration & dosage; D007538:Isoniazid / Q000627:therapeutic use*; D007958:Leukocyte Count; D008297:Male; D011696:Purpura, Thrombocytopenic / Q000139:chemically induced; D012293:Rifampin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D014397:Tuberculosis, Pulmonary / Q000097:blood / Q000188:drug therapy / Q000276:immunology*
D007490:Iproniazid; D007538:Isoniazid; D012293:Rifampin